Sonelokimab
Hidradenitis Suppurativa (HS)
Key Facts
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is on a mission to revolutionize treatment for serious inflammatory diseases by leveraging its innovative Nanobody® technology. The company's core achievement is the in-licensing and rapid advancement of sonelokimab, which has demonstrated positive Phase 2 results and is now in multiple Phase 3 trials for hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). Its strategy focuses on executing these late-stage programs to bring a potentially best-in-class therapy to market in competitive immunology spaces, while exploring expansion into adjacent indications like axial spondyloarthritis and palmoplantar pustulosis.
View full company profileAbout MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is on a mission to revolutionize treatment for serious inflammatory diseases by leveraging its innovative Nanobody® technology. The company's core achievement is the in-licensing and rapid advancement of sonelokimab, which has demonstrated positive Phase 2 results and is now in multiple Phase 3 trials for hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). Its strategy focuses on executing these late-stage programs to bring a potentially best-in-class therapy to market in competitive immunology spaces, while exploring expansion into adjacent indications like axial spondyloarthritis and palmoplantar pustulosis.
View full company profileAbout MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is on a mission to revolutionize treatment for serious inflammatory diseases by leveraging its innovative Nanobody® technology. The company's core achievement is the in-licensing and rapid advancement of sonelokimab, which has demonstrated positive Phase 2 results and is now in multiple Phase 3 trials for hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). Its strategy focuses on executing these late-stage programs to bring a potentially best-in-class therapy to market in competitive immunology spaces, while exploring expansion into adjacent indications like axial spondyloarthritis and palmoplantar pustulosis.
View full company profileAbout MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is on a mission to revolutionize treatment for serious inflammatory diseases by leveraging its innovative Nanobody® technology. The company's core achievement is the in-licensing and rapid advancement of sonelokimab, which has demonstrated positive Phase 2 results and is now in multiple Phase 3 trials for hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). Its strategy focuses on executing these late-stage programs to bring a potentially best-in-class therapy to market in competitive immunology spaces, while exploring expansion into adjacent indications like axial spondyloarthritis and palmoplantar pustulosis.
View full company profileAbout MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is on a mission to revolutionize treatment for serious inflammatory diseases by leveraging its innovative Nanobody® technology. The company's core achievement is the in-licensing and rapid advancement of sonelokimab, which has demonstrated positive Phase 2 results and is now in multiple Phase 3 trials for hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). Its strategy focuses on executing these late-stage programs to bring a potentially best-in-class therapy to market in competitive immunology spaces, while exploring expansion into adjacent indications like axial spondyloarthritis and palmoplantar pustulosis.
View full company profileAbout MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is on a mission to revolutionize treatment for serious inflammatory diseases by leveraging its innovative Nanobody® technology. The company's core achievement is the in-licensing and rapid advancement of sonelokimab, which has demonstrated positive Phase 2 results and is now in multiple Phase 3 trials for hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). Its strategy focuses on executing these late-stage programs to bring a potentially best-in-class therapy to market in competitive immunology spaces, while exploring expansion into adjacent indications like axial spondyloarthritis and palmoplantar pustulosis.
View full company profileAbout MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is on a mission to revolutionize treatment for serious inflammatory diseases by leveraging its innovative Nanobody® technology. The company's core achievement is the in-licensing and rapid advancement of sonelokimab, which has demonstrated positive Phase 2 results and is now in multiple Phase 3 trials for hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). Its strategy focuses on executing these late-stage programs to bring a potentially best-in-class therapy to market in competitive immunology spaces, while exploring expansion into adjacent indications like axial spondyloarthritis and palmoplantar pustulosis.
View full company profileTherapeutic Areas
Other Hidradenitis Suppurativa (HS) Drugs
| Drug | Company | Phase |
|---|---|---|
| Izokibep (Partnered) | Affibody | Phase 3 |
| ELN28 | Elasmogen | Pre-clinical |
| Topical Roflumilast Foam 0.3% | Arcutis Biotherapeutics | Phase 2 |
| Tibulizumab (ZB-106) | Zura Bio | Phase 2 |